Juliet Singh
Vorstandsvorsitzender bei Transdel Pharmaceuticals Holdings, Inc.
Profil
Juliet Singh is currently the Chief Executive Officer at Transdel Pharmaceuticals Holdings, Inc. She previously worked as the Chairman, President & Chief Executive Officer at Harrow, Inc. from 2009 to 2010.
Prior to that, she was the Director-Worldwide Regulatory Affairs at Allergan, Inc. from 1996 to 2000.
She also worked as the VP-Regulatory Affairs & Quality Assurance at Collateral Therapeutics, Inc. from 2003 to 2005.
Additionally, she held the position of Assistant Director-Regulatory Affairs at Baxter Healthcare Corp.
Dr. Singh earned a doctorate degree from the University of California, Davis.
Aktive Positionen von Juliet Singh
Unternehmen | Position | Beginn |
---|---|---|
Transdel Pharmaceuticals Holdings, Inc.
Transdel Pharmaceuticals Holdings, Inc. Other Metals/MineralsNon-Energy Minerals Part of Harrow, Inc., Transdel Pharmaceuticals Holdings, Inc. is a company that specializes in the offices of other holding companies. The company is based in Escondido, CA. Juliet Singh has been the CEO of the company since 2005. | Vorstandsvorsitzender | 01.01.2005 |
Ehemalige bekannte Positionen von Juliet Singh
Unternehmen | Position | Ende |
---|---|---|
HARROW, INC. | Vorsitzender | 17.02.2010 |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | General Counsel | 01.01.2005 |
ALLERGAN, INC. | General Counsel | 01.01.2000 |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | - |
Ausbildung von Juliet Singh
University of California, Davis | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
HARROW, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Allergan, Inc.
Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | Commercial Services |
Transdel Pharmaceuticals Holdings, Inc.
Transdel Pharmaceuticals Holdings, Inc. Other Metals/MineralsNon-Energy Minerals Part of Harrow, Inc., Transdel Pharmaceuticals Holdings, Inc. is a company that specializes in the offices of other holding companies. The company is based in Escondido, CA. Juliet Singh has been the CEO of the company since 2005. | Non-Energy Minerals |